ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.350
+0.110 (8.87%)
At close: Jan 9, 2026, 4:00 PM EST
1.400
+0.050 (3.70%)
After-hours: Jan 9, 2026, 7:18 PM EST
ALX Oncology Holdings Employees
ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.
Employees
80
Change (1Y)
8
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,350,125
Market Cap
73.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALXO News
- 3 days ago - ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 days ago - ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - GlobeNewsWire
- 5 weeks ago - ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - GlobeNewsWire
- 7 weeks ago - ALX Oncology to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting - GlobeNewsWire
- 2 months ago - ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - GlobeNewsWire